STAT and Janus kinase targeting by human herpesvirus 8 interferon regulatory factor in the suppression of type-I interferon signaling.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
07 2022
Historique:
received: 30 01 2022
accepted: 15 06 2022
revised: 22 07 2022
pubmed: 2 7 2022
medline: 27 7 2022
entrez: 1 7 2022
Statut: epublish

Résumé

Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma (KS)-associated herpesvirus, is involved etiologically in AIDS-associated KS, primary effusion lymphoma (PEL), and multicentric Castleman's disease, in which both viral latent and lytic functions are important. HHV-8 encodes four viral interferon regulatory factors (vIRFs) that are believed to contribute to viral latency (in PEL cells, at least) and/or to productive replication via suppression of cellular antiviral and stress signaling. Here, we identify vIRF-1 interactions with signal transducer and activator of transcription (STAT) factors 1 and 2, interferon (IFN)-stimulated gene factor 3 (ISGF3) cofactor IRF9, and associated signal transducing Janus kinases JAK1 and TYK2. In naturally infected PEL cells and in iSLK epithelial cells infected experimentally with genetically engineered HHV-8, vIRF-1 depletion or ablation, respectively, led to increased levels of active (phosphorylated) STAT1 and STAT2 in IFNβ-treated, and untreated, cells during lytic replication and to associated cellular-gene induction. In transfected 293T cells, used for mechanistic studies, suppression by vIRF-1 of IFNβ-induced phospho-STAT1 (pSTAT1) was found to be highly dependent on STAT2, indicating vIRF-1-mediated inhibition and/or dissociation of ISGF3-complexing, resulting in susceptibility of pSTAT1 to inactivating dephosphorylation. Indeed, coprecipitation experiments involving targeted precipitation of ISGF3 components identified suppression of mutual interactions by vIRF-1. In contrast, suppression of IFNβ-induced pSTAT2 was effected by regulation of STAT2 activation, likely via detected inhibition of TYK2 and its interactions with STAT2 and IFN type-I receptor (IFNAR). Our identified vIRF-1 interactions with IFN-signaling mediators STATs 1 and 2, co-interacting ISGF3 component IRF9, and STAT-activating TYK2 and the suppression of IFN signaling via ISGF3, TYK2-STAT2 and TYK2-IFNAR disruption and TYK2 inhibition represent novel mechanisms of vIRF function and HHV-8 evasion from host-cell defenses.

Identifiants

pubmed: 35776779
doi: 10.1371/journal.ppat.1010676
pii: PPATHOGENS-D-22-00189
pmc: PMC9307175
doi:

Substances chimiques

Interferon Regulatory Factors 0
Interferon Type I 0
STAT1 Transcription Factor 0
STAT2 Transcription Factor 0
Janus Kinases EC 2.7.10.2

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1010676

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI140855
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Virol. 2000 Apr;74(7):3388-98
pubmed: 10708456
Science. 1996 Dec 6;274(5293):1739-44
pubmed: 8939871
Mol Cell. 2015 Jan 22;57(2):349-60
pubmed: 25544563
Blood. 2008 Jan 1;111(1):320-7
pubmed: 17890449
PLoS Pathog. 2010 Aug 05;6(8):e1001031
pubmed: 20700448
J Biol Chem. 2016 Mar 18;291(12):6281-91
pubmed: 26786098
Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3840-5
pubmed: 16497831
J Virol. 2018 Mar 14;92(7):
pubmed: 29343584
J Virol. 2004 Jun;78(12):6621-35
pubmed: 15163753
EMBO J. 2013 Oct 16;32(20):2751-63
pubmed: 24065129
J Virol. 2009 May;83(10):5056-66
pubmed: 19279093
Genes Dev. 2006 Dec 15;20(24):3372-81
pubmed: 17182865
Biochem J. 2015 Mar 15;466(3):511-24
pubmed: 25564224
Nat Rev Immunol. 2012 Jan 06;12(2):125-35
pubmed: 22222875
Oncogene. 2001 Feb 15;20(7):800-11
pubmed: 11314014
J Virol. 2021 Apr 12;95(9):
pubmed: 33597212
J Biol Chem. 2019 Jun 14;294(24):9503-9517
pubmed: 31040183
Nat Struct Mol Biol. 2011 Nov 06;18(12):1336-44
pubmed: 22056774
J Virol Methods. 2011 Jun;174(1-2):12-21
pubmed: 21419799
Cytokine. 2010 Apr;50(1):1-14
pubmed: 20036577
J Virol. 2015 Oct 28;90(1):506-20
pubmed: 26512076
Cancer Res. 2009 Apr 15;69(8):3673-80
pubmed: 19351818
Virology. 2017 Jul;507:161-169
pubmed: 28441586
J Virol. 2020 Jan 6;94(2):
pubmed: 31666375
J Biol Chem. 1997 Feb 14;272(7):4600-5
pubmed: 9020188
J Biol Chem. 1997 Aug 8;272(32):20070-6
pubmed: 9242679
Mol Cell Biol. 2000 Nov;20(21):8254-63
pubmed: 11027294
J Virol. 2003 Jul;77(13):7635-44
pubmed: 12805463
J Gen Virol. 2011 Oct;92(Pt 10):2394-2398
pubmed: 21697347
J Gen Virol. 2003 Jun;84(Pt 6):1471-1483
pubmed: 12771416
Oncogene. 1997 Oct 16;15(16):1979-85
pubmed: 9365244
J Virol. 1998 Jul;72(7):5433-40
pubmed: 9620998
Cytotechnology. 2010 Jan;62(1):73-82
pubmed: 20309632
J Virol. 2015 Apr;89(8):4227-36
pubmed: 25631085
J Virol. 2008 Nov;82(21):10444-54
pubmed: 18701593
J Virol. 2012 Mar;86(5):2769-79
pubmed: 22171275
J Virol. 2017 Apr 28;91(10):
pubmed: 28250121
Sci Rep. 2019 Mar 20;9(1):4902
pubmed: 30894629
PLoS Pathog. 2019 May 6;15(5):e1007743
pubmed: 31059555
J Virol. 2002 Sep;76(17):8797-807
pubmed: 12163600
J Biol Chem. 2004 Sep 17;279(38):39199-206
pubmed: 15175343
J Virol. 2003 Apr;77(7):4205-20
pubmed: 12634378
Proc Natl Acad Sci U S A. 2010 May 4;107(18):8369-74
pubmed: 20404187
J Virol. 2013 Dec;87(24):13676-93
pubmed: 24109218
J Virol. 2017 Oct 27;91(22):
pubmed: 28878084
Biol Chem. 2017 Jul 26;398(8):857-870
pubmed: 28455950
J Virol. 2015 Aug;89(15):7979-90
pubmed: 26018151
Nat Microbiol. 2019 Jun;4(6):914-924
pubmed: 30936491
J Virol. 1999 Apr;73(4):3040-53
pubmed: 10074154
J Exp Med. 2005 May 16;201(10):1543-53
pubmed: 15883169
J Virol. 2013 Sep;87(17):9398-410
pubmed: 23785197
EMBO J. 2003 Feb 3;22(3):537-47
pubmed: 12554654
J Interferon Cytokine Res. 1997 Mar;17(3):121-34
pubmed: 9085936
Cytokine Growth Factor Rev. 2016 Jun;29:35-43
pubmed: 26987614
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4306-15
pubmed: 26199418
J Virol. 1999 Sep;73(9):7334-42
pubmed: 10438822
PLoS Pathog. 2012;8(6):e1002748
pubmed: 22685405
Cancer Res. 2005 Mar 1;65(5):1738-47
pubmed: 15753369
Virology. 2020 Feb;541:160-173
pubmed: 32056714

Auteurs

Qiwang Xiang (Q)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.

Zunlin Yang (Z)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.

John Nicholas (J)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH